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Immune Cell Activation: 
Stimulation, Costimulation, and 
Regulation of Cellular Activation
Suman Kapur and Anuradha Pal
Abstract
Opiate receptor (uOR) is expressed in central nervous system, gastrointestinal 
tract, male and female reproductive tissues, and immune cells. Morphine, a ligand 
for opioid receptor family, is known to activate the hypothalamic-pituitary-adrenal  
axis and release immunosuppressive glucocorticoids. Herein we present that 
minor changes, in the form of nonsynonymous single nucleotide polymorphisms, 
in μOR have cumulative impact on receptor-mediated signaling and functions of 
specific cell type(s). Significant reduction was seen in cells in M and S phases with 
coactivation of immune receptors with μOR. Flow cytometry-based experiments 
established a reduction in B and T lymphocytes, NK cells, and macrophages. 
Differences in types of immune cells were found to be significant to reduce 
immune response(s) mounted by GG(mutant allele)-bearing individuals. This is 
the first report on cross-talk between LPS-binding and μOR, explaining the reduc-
tion in the number of T and B cells after chronic opiate use and also the associa-
tion of this impact on immunocytes with functional SNP, rs1799972/118G allele 
of OPRM1 gene as an explanation for the immune suppression in opiate users. 
Initially present lower cell titers can be further lowered by exogenous opiates and 
account for immunosuppression seen in chronic opiate users or after long-term 
treatment with opiate drugs for chronic pain.
Keywords: immune response activation, costimulation, cellular activation,  
opioid receptors
1. Immune system: a brief introduction
The immune system is a complex and highly developed system, yet its mission 
is simple: to seek and kill intruders. It is the body’s defense system against infec-
tious organisms and other invaders. The purpose of the immune system is to keep 
infectious microorganisms, such as bacteria, viruses, and fungi, out of the body, 
and to destroy any infectious microorganisms that do invade the body. Through 
a series of steps called the immune response, the immune system protects us 
against invading organisms. It is a network of cells, tissues, and organs working 
together to protect the body. The most important cell types involved in immune 
response are white blood cells, which come in two basic types that combine to 
seek out and destroy disease-causing organisms. Leukocytes are produced or 
stored in different locations in the body, like the thymus, spleen, bone marrow 
lymph nodes, and special deposits of lymphoid tissue (as in the gastrointestinal 
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Cell type Location and function
Leukocytes Derived from myeloid or lymphoid lineage, these are 
the main cells in immune system, which provide either 
innate or specific adaptive immunity. Myeloid cells 
include phagocytic, motile neutrophils, monocytes, 
and macrophages, providing the first-line defense 
against pathogens. Other myeloid cells involved in 
defense against parasites & in genesis of allergic 
reactions include eosinophils, basophils, & mast cells. 
Lymphocytes regulate the action of other leukocytes & 
generate specific responses to prevent chronic/recurrent 
infections [1]
B cells In mammals, B cells mature in the bone marrow where 
as in birds, B cells mature in the bursa of Fabricius, a 
lymphoid organ first discovered by Chang and Glick [2]. 
They develop into antibody-secreting plasma cells. B cells 
express B cell receptors (BCRs) on their cell membrane 
that allows them to bind to specific antigen, against which 
it initiates a specific antibody response.
T cells Originate in the bone marrow and mature in the thymus 
giving rise to helper, regulatory, cytotoxic T cells, or 
memory T cells. From the thymus, they migrate to 
peripheral tissues, blood, & lymphatic system. On 
stimulation, they secrete chemical messengers called 
cytokines, which stimulate the differentiation of B cells 
into antibody-producing cells also called plasma cells. 
Cytotoxic T cells in the presence of various cytokines bind 
to and kill infected and/or cancer cells.
T helper cells Subset of T cells, found throughout the body, with 
especially high titers in lymphoid organs (lymph nodes and 
spleen), as well as the liver, lung, blood, and the intestinal 
tract. T helper TH or CD4+ T cells coordinate and regulate 
immunological responses. TH cells mediate responses by 
secreting lymphokines that act on other cell types involved 
in mounting an immune response.
T cytotoxic cells Subset of T cells, found throughout the body, with 
especially high titers in lymphoid organs (lymph nodes & 
spleen), as well as the liver, lung, blood, and the intestinal 
tract. T cytotoxic Tc or CD8+ T cells are involved in 
directly killing virus-infected cells, transplanted cells, and 
sometimes, eukaryotic parasites and tumor cells. CD8+ T 
cells have been shown to play a role in downregulating the 
immune response.
Natural Killer cells NK cells are similar to Tc cells. They directly kill certain 
tumors such as melanomas, lymphomas and virus-infected 
cells- and clear herpes and cytomegalovirus-infected cells. 
In contrast to Tc cells, NK cells kill their target cells more 
effectively without the need for recognition of antigen 
in association with MHC molecules and are activated by 
secretions from TH cells.
Macrophages These are phagocytic cells and function as antigen-
presenting cells (APCs) as they ingest foreign materials 
and present these to other members of the immune 
system such as T cells and B cells. Besides being the 
initiators of an immune response, they also act as immune 
modulators by secreting cytokines and can also be 
stimulated by lymphokines, to exhibit increased levels of 
phagocytosis.
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tract). These cells circulate through the body between the organs and nodes via 
lymphatic and blood vessels, and work in a coordinated manner to monitor the 
body for foreign invasions. A potent and active immune system is vital for staying 
healthy. The immune system differentiates between invaders and the body’s own 
cells—when immune system is not able to differentiate between self and nonself, 
a reaction against “self ” cells and molecules causes autoimmune disease. The 
immune system will remain active by getting enough sleep, exercise, and good 
nutrition.
Immune response leads to inflammation. The goal of inflammation is to get 
rid of the stimulus—both the disease-causing pathogens and/or neoplastic tissue. 
Significant steps involved in inflammation include recruitment of immune cells, 
interactions of these cells in the affected tissue and activation pattern of the inter-
acting cells. The immune system continuously looks for pathogens, xenobiotics, 
and other nonself signals. Thus, the cell types of the immune system are incredibly 
dynamic and capable of upregulating processes required for handling these insults 
Cell type Location and function
Dendritic cells Originate in the bone marrow and form another class 
of APCs. These are found in the lymphoid organs such 
as the thymus, lymph nodes, and spleen along with the 
bloodstream and other tissues. They function to capture 
and process antigens in lymphoid organs at the time of 
initiation of an immune response.
Neutrophils These cells, which ingest, kill, and digest pathogens, 
are the most highly adherent and motile, phagocytic 
leukocytes; the first cell types to be recruited to acute 
inflammatory sites. Their functions are dependent 
on adherence molecule CD11b/CD18, or biochemical 
pathways, such as the respiratory burst associated with 
cytochrome b558.
Eosinophils Defend against parasites and participate in hypersensitivity 
reactions. Their cytotoxicity is mediated through 
cytoplasmic granules containing eosinophilic basic and 
cationic proteins.
Basophils Along with their tissue counterparts, mast cells produce 
cytokines required for defense against parasites and 
allergic inflammation. They display surface membrane 
receptors for IgE antibodies and possess cytoplasmic 
granules containing heparin and histamine. When 
cell-bound IgE antibodies are cross linked by antigens, the 
eosinophils degranulate releasing low-molecular weight 
vasoactive mediators (e.g., histamine), which mediate 
their biological effects.
Monocytes/macrophages These are involved in phagocytosis and intracellular 
killing of microorganisms. Macrophages are 
differentiated monocytes, residing in the 
reticuloendothelial systems and act as antigen-presenting 
cells presenting processed peptides to T cells. They are 
recruited to inflammatory sites and further activated 
by exposure to certain cytokines, which potentiate their 
biologic functions.
Table 1. 
Major cell types of adaptive immunity.
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on a time scale of minutes to hours. Several cell types in this system are capable 
of activation to secrete cytokines, rapidly proliferate, or otherwise communicate 
to surrounding cells that there is a pathogen to consider. Upon clearance of the 
pathogen, the cell population must contract in a controlled manner. Furthermore, 
in some cell populations (e.g., T cells), a subset of cells is retained as long-lived 
memory cells to protect and prime the system for future insults. Researchers are 
increasingly focused on early events in immune cell activation, where the response 
to an inflammatory signal can be tuned to impact overall cell function. In areas such 
as immuno-oncology, increased activation is connected to improve cell expan-
sion whereas in the field of immunosuppression, the converse is desired. Clinical 
successes in targeting the immune system for treating cancer have generated a 
resurgence of effort to harness the immune system more routinely for therapeutic 
intervention (Table 1).
2. Mechanism of activation of adapted immunity
Adaptive immune responses carried out by lymphocytes are of two broad 
classes:
• antibody responses carried out by B cells
• cell-mediated immune responses carried out by T cells
During an immune response, the B cells are activated to secrete immunoglobu-
lins, which circulate in blood, permeate to other body fluids, and bind specifically 
to foreign antigen that stimulated their production in the first place. This binding 
inactivates viruses and microbial toxins by blocking their interaction with the host 
cells. Antibody binding also marks invading pathogens for destruction by phago-
cytic cells of the innate immune system [3].
Cell-mediated reactions depend on direct interactions between T lympho-
cytes and cells bearing the antigen that the T cells recognize. T cells are special-
ized to recognize foreign antigens as peptide fragments bound to proteins of 
the major histocompatibility complex (MHC). The cytotoxic T cells recognize 
any infected cells with the help of viral antigens displayed on the surface of the 
infected cells [1]. Other T lymphocytes that activate the cells they recognize 
are marked by the expression of the cell-surface molecule CD4 on helper T 
cells. The CD4 T lymphocytes can be divided into two subsets, which carry out 
different functions by defending the body particularly from bacterial infec-
tions. Bacteria phagocytosed by macrophages are destroyed in the lysosomes, 
which contain several enzymes and antimicrobial substances. The intracellular 
bacteria, as in case of tuberculosis (Mtb), survive, because the vesicles they 
occupy do not fuse with the lysosomes. These infections are modified by a 
subset of CD4 T cells, namely TH1 cells, which activate macrophages, induce 
fusion of lysosomes and phagocytic vesicles containing the bacteria, and at the 
same time stimulate other antibacterial mechanisms of the phagocyte. CD4+ T 
cells play critical role during Mtb infection by mediating protection, contribut-
ing to inflammation, and regulating immune response. Th1 and Th17 cells are 
the main effector CD4+ T cells during Mtb. Th1 cells release cytokines and 
chemokines that attract phagocytes to the site of infection and impart protec-
tion from Mtb by secreting IFN-γ and activating antimycobacterial action in 
macrophages.
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T cells not only destroy intracellular pathogens by killing infected cells and by 
activating macrophages, but they also have a central role in the destruction of extra-
cellular pathogens by activating B cells. This is the specialized role of the second 
subset of CD4 T cells called TH2 cells with special properties that can activate naive 
B lymphocytes. Most antigens require an accompanying signal from helper T cells 
before they can stimulate B cells to proliferate and differentiate into cells secreting 
antibody. Cytotoxic T cells and TH1 cells interact with antigens produced by patho-
gens that have infected the target cell or that have been ingested by it. Helper T cells, 
in contrast, recognize and interact with B cells that have bound and internalized 
foreign antigen by means of their surface immunoglobulin.
Antigen-specific activation of effector T cells is aided by coreceptors that distin-
guish between the two classes of MHC molecule—CD8 coreceptor bearing cytotoxic 
cells that binds MHC class I molecules, whereas TH1 and TH2 cells express the CD4 
coreceptor with specificity for MHC class II molecules. The maturation of T cells into 
either CD8 or CD4 T cells reflects the type of T-cell receptor specificity that occurs dur-
ing development, and the selection of T cells that can receive survival signals from self-
MHC molecules. On recognizing their targets, the three types of T cell are stimulated 
to release different sets of effector molecules namely, cytokines, which play crucial role 
in the clonal expansion of lymphocytes as well as in the innate immune responses.
T cells are thus crucially important for both humoral and cell-mediated responses 
of adaptive immunity. The adaptive immune response seems to have engrafted specific 
antigen recognition by highly diversified receptors onto innate defense systems, which 
have a central role in the effector actions of both B and T lymphocytes. The vital role of 
adaptive immunity in fighting infection is illustrated by the immunodeficiency and/or 
autoimmune diseases and the problems caused by pathogens that succeed in evading or 
subverting an adaptive immune response. The antigen-specific suppression of adaptive 
immune responses is the goal of treatment for important human diseases involving 
inappropriate activation of lymphocytes, whereas the specific stimulation of an adaptive 
immune response is the basis of successful vaccination for several childhood infections.
3. Opioid receptor and immune function
As early as 1987, Jankovic and Maric [4] showed that the neuropeptides—
methionine-enkephalin, and leucine-enkephalin, exhibit a protective action against 
anaphylactic shock in rats sensitized to ovalbumin. Subsequent studies have shown 
that enkephalins can act both as suppressors and potentiators of immune response in 
a dose-dependent manner. Animal studies, where nutritional status, environmental 
influences, history of drug abuse, and genetic variability can be controlled more 
easily, have shown that morphine treatment results in significant immune deficits. 
Chronic morphine use has been shown to result in severe immunosuppression, 
posing as a significant risk factor for opportunistic infection [5], and this finding 
is also supported by epidemiological studies that show an increased prevalence of 
opportunistic infections in opiate users [6]. Chronic morphine has been shown to 
effect early reactions of innate immunity and later responses of adaptive immunity 
against microbes [7]. In addition, morphine has also been shown to affect the brain-
immune axis by an IL-1β-dependent pathway [8]. Various studies support the idea 
that chronic morphine exposure in vivo attenuates lymphocyte proliferation [9], NK 
cell cytotoxicity [10], antibody and serum hemolysin formation [11], and phagocytic 
properties of peripheral mononuclear leukocytes [12]. Morphine exposure has also 
been shown to increase mortality of infected mice [12–14]. Novick et al. [15] showed 
that long-term abuse of opiates results in impaired NK cell activity and altered CD4+ 
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and CD8+ T cell numbers. In animal models, parenteral use of opiates was shown to 
inhibit mitogenic and effector cell responses in both B and T cells [9, 16].
3.1 Opioid receptors in various immune cell types and their functional 
implications
Molecular biology studies have shown that immune cells differentially express 
opioid receptors (OR), and morphine affects their development, differentiation, 
and function [17]. Binding sites and protein expression for delta (δ) and kappa (κ) 
subclasses of G protein-coupled ORs [18, 19], in addition to gene expression of δ, 
κ, and μ subclasses [20, 21], have been described in leukocytes. Chuang et al. [20] 
reported the presence of mRNA for the μOR in human T- and B-cell lines, CD4+ 
T cells, monocytes, macrophages and granulocytes. Retinoid receptor activation 
increases the expression of the μOR in U937 cells, a mononuclear cell line [22]. Mu 
(μ-), Kappa (κ-), and Delta (δ-) opioids have been shown to possess chemoattrac-
tant activity and induce the chemotaxis of both monocytes and neutrophils [23–28]. 
Simpkins et al. [24] and Van Epps and Saland [25] showed that opiates, acting 
through δ and μ subclasses of OR expressed on human monocytes and neutrophils, 
are capable of inhibiting subsequent migratory responses to chemokines, and that 
this process of heterologous desensitization/trans-deactivation is associated with 
phosphorylation of chemokine receptors. Grimm et al. [26] showed that phago-
cytes respond chemotactically, with a chemotaxis index 2- to 2.5-fold higher than 
controls, to met-enkephalin and morphine, and this chemotaxis was inhibited by 
the OR antagonist naloxone. Liu et al. [27] demonstrated that pretreatment with 
opioids, including morphine, heroin, met-enkephalin, the selective μ-agonist 
DAMGO, or the selective δ-agonist [D-Pen2, D-Pen5] enkephalin (DPDPE), leads 
to the inhibition of the chemotactic response of leukocytes to complement-derived 
chemotactic factors. They also affect the chemokines macrophage inflammatory 
protein (MIP-1α)/CCL3, RANTES/CCL5, monocyte chemotactic protein-1 (MCP-
1)/CCL2, and IL-8/CXCL8 [28]. Many investigators choose to study the effects of 
morphine on immune function because morphine has clinical applications and 
shows good affinity for all three types of ORs. However, use of morphine as the 
opioid of choice has limited the ability to delineate, which type of OR mediates the 
given immunological response/s due to binding to all receptor types.
Existence of a low-affinity, naloxone-insensitive morphine binding site on human 
peripheral blood macrophages has also been reported [29]. Opioid alkaloids, such 
as morphine and the endogenous peptides, including β-endorphin and dynorphin, 
directly modulate the function of lymphocytes and other cells involved in host defense 
and immunity, ORs preferentially bind to the (−)-enantiomer of most opioid alkaloids, 
for example, ORs will bind the antagonist (−)-naloxone but not (+)-naloxone [30].
3.2 Immunosuppression mediated by opiates
The role of opiate drugs in suppressing a variety of immunological endpoints 
such as proliferation, functions and responses of both T and B cells, and attenu-
ation of the cytokine system has been studied extensively [31, 32]. Opiate drug 
administration has also been reported to suppress movement and number of white 
blood cells [33, 34]. Heroin use has been documented to depress E-rosette forma-
tion indicating clinical immune suppression [35]. Long-term use of opiate drugs 
has been reported to depress T cell reactivity and cause a loss of T helper (TH) cells 
[36, 37], reduces T helper/T cytotoxic cell ratios, and decreases T helper cell func-
tion [38–41]. Use of opiate drugs produces atrophy of lymphoid organs, decreases 
lymphoid content, and alters antigen-specific antibody production [42, 43]. Opiate 
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addiction induces immunonutritional deficiencies [44, 45] and impairs immuno-
globulin synthesis and function [46]. Naik et al. [47] showed a decrease of IgA levels 
and increase of IgG levels in Indian opiate users as compared to nonusers. Opioids 
bind directly on immune cells and modulate the function of these cells and also bind 
to classical ORs in the CNS, causing the release of catecholamines and/or steroids, 
which in turn also affect the immune cells. At the same time, morphine is known to 
activate the hypothalamic-pituitary-adrenal axis and release glucocorticoids, which 
are immunosuppressive in their own capacity [48].
3.3 Impact of functional polymorphism in OPRM1 gene on cell function
Several studies suggest that immune cells contain μORs along with existence 
of morphine binding sites differing from classical μORs, and measurements of the 
mRNAs that encode the neuronal types of OR show low levels of receptor mRNA 
in immune cells [49]. μOR is known to depict a total of 43 variants within cod-
ing and noncoding regions of the OPRM1 gene, and 52 different haplotypes were 
predicted in the subgroup of African Americans. These haplotypes were classified 
by similarity clustering into functionally related categories, and one of these was 
significantly more frequent in substance-dependent individuals, viz. [−1793T-A, 
−1699insT, −1320A-G, −111C-T, +17C-T (+118A-G)], which was associated with 
substance dependence [50]. Studies evaluating the effects of 118A > G SNP on the 
intracellular signaling cascades resulting from μ-OR activation have shown conflict-
ing results. Both DAMGO and morphine were twofold more potent in inhibiting 
calcium channel currents in sympathetic neurons transfected with the 118G allele 
than in neurons expressing the wild-type receptors [51]. However, Kroslak et al. 
[52] showed in HEK293 and AV-12 cells that stable expression of the 118G variant 
was associated with decreased agonist-mediated cyclic adenosine monophosphate 
(cAMP) signaling for morphine, methadone, and DAMGO, but not for β-endorphin. 
These results suggest that cellular environment may influence the phenotype 
associated with the variant receptor. Deb et al. [53], using murine neuroblastoma 
Neuro 2 A cells stably transfected with cDNA containing 118G variant, studied the 
effect on PKA, ERK, and CREB activation and documented no upregulation of 
PKA activity but a differential response of ERK phosphorylation in comparison to 
118A variant, following chronic morphine treatment. Zhang et al. [54] analyzed 87 
human brain tissue samples derived from autopsies and performed in vitro experi-
ments on Chinese hamster ovary (CHO) cells, to show that the amount of mRNA 
transcribed from the 118G allele was twofold lower than the mRNA derived from the 
118A allele. The levels of variant protein were ten-fold lower compared with those of 
the wild-type receptor. They also showed that after transfection into CHO cells with 
a cDNA representing only the coding region of OPRM1 and inhibition of transcrip-
tion with actinomycin D, the mRNA turnover was same for 118A and 118G variants. 
An in silico study by Pang et al. [55] showed that the substitution of the A with G at 
position 118 of the OPRM1 gene abolishes three transcription factor binding sites, 
while creating a novel exon splice enhancer as well as p53 and a zinc finger protein 
binding sites, predicting a direct effect of 118A > G on gene expression and on the 
processing of heterogeneous nuclear RNA into mature mRNA. Huang et al. [56] 
described the role of the 118A > G SNP in posttranslational mechanisms suggesting 
that N-glycosylation may affect receptor expression, since it plays an important 
role in correct folding of receptors in the endoplasmic reticulum and, hence, their 
sorting from the endoplasmic reticulum to the plasma membrane. Huang et al. 
[56] also showed that the variant receptor had lower relative molecular mass than 
the wild-type one, which may be explained by a differential glycosylation status 
between the two receptors. Pulse-chain (or chase) experiments revealed that the 
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half-life of the mature form of the variant receptor (~12 h) was shorter than that of 
the wild-type receptor (~28 h) showing its effect on protein stability. Thus, several 
lines of evidence suggest that the 118G variant may affect OPRM1 gene expression 
in addition to mRNA translation, posttranslational processing, or turnover of the 
μ-opioid receptor protein, which can all effect signaling pathway/s.
3.4 Epigenetics of OPRM1 gene and its impact on cell function
Human genome has about 45,000-C-phosphate-G-(CpG) islands, many in the 
promoter regions of genes. The CpG islands are located upstream of the transcrip-
tion start site to within the first exon [57]. Nielsen et al. [58] and Chorbov et al. [59] 
reported that in DNA obtained from peripheral lymphocytes, two of 16 CpG sites 
in a region of OPRM1 gene promoter had significantly higher methylation in former 
heroin addicts than in controls. These two CpG sites are located in binding sites for 
the potential Sp1 transcription factor. Oertel et al. [60] showed that substitution of an 
A with a G at gene position +118 introduces a new CpG-methylation site at position 
+117, which leads to enhanced methylation of OPRM1 gene resulting in decreased 
expression. Using m-fold software, Johnson et al. [61] showed that 118G variant 
demonstrated an altered folding that could affect mRNA stability. The epigenetic 
mechanism reported by Oertel et al. [60] impedes μ-OR upregulation in brain tissue, 
and they concluded that while in wild-type subjects, a reduced signaling efficiency 
associated with chronic heroin exposure was compensated for by an increased recep-
tor density; this upregulation was absent in carriers of the 118G receptor variant due 
to diminished OPRM1 mRNA transcription. The OPRM1 118A > G SNP variant not 
only reduces μ-OR signaling efficiency, but by a genetic-epigenetic interaction, also 
reduces OR expression and therefore, depletes the opioid system of a compensatory 
reaction to chronic exposure, providing evidence that a change in the genotype can 
cause a change in the epigenotype with major functional consequences.
3.5 Receptor-receptor interactions
Oligomerization is a general characteristic of cell membrane receptors that is 
shared by G protein-coupled receptors (GPCRs). GPCRs do not exist in isolation 
and interact with components of the bilayer, such as lipids and sterols, as well 
as with other GPCRs to form dimers and higher order oligomers, which are of 
functional significance as this affects the ligand binding and signaling properties 
of GPCRs [62, 63]. Recent studies of these complexes, both in vivo and in purified 
reconstituted forms, unequivocally support this contention for GPCRs [64]. A 
large number of direct binding assays indicating negative or positive cooperativity 
suggest clustering of GPCRs [65]. Mansoor et al. [66] reported that GPCRs can 
come together in the presence of lipids. Oligomerization and the two monomers 
comprising a GPCR dimer could be nonequivalent, thereby allowing more refined 
regulation of GPCR activity [66–68]. Thus, GPCR dimerization can be the result of 
the receptors forming heterodimers as well as homodimers [69], with many dimers 
displaying modified pharmacology [70], altered responsiveness to viral entry 
through GPCRs [71], or attenuated signaling [72]. Therefore, it is apparent that the 
oligomeric potential of GPCRs allows further diversification of their repertoire as 
a result of more complex ligand-receptor relationships than envisioned for mono-
meric receptors due to a more complex ligand-receptor relationship [64]. Although 
monomeric GPCRs can activate G proteins, the pentameric structure constituted by 
one GPCR homodimer and one heterotrimeric G protein may constitute the func-
tional unit, and oligomeric entities can be viewed as multiples of dimers [73].
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3.6 Interactions of opioid receptors
Fluorescence correlation spectroscopy (FCS) studies suggest that μ-opioid 
receptors exist primarily as dimers that oligomerize with δ-opioid receptors into 
tetramers [74]. High-resolution crystallographic structures of the μ-opioid by 
Manglik et al. [75] showed that they exist as parallel dimers and/or tetramers. 
Some TM domains have been observed more often than others. TM5 and TM6 resi-
dues constituted the main interfaces for the μ-opioid receptor crystallized dimers, 
with extensive contacts throughout the length of these TM helices in μ-opioid 
receptor dimers. The μ-opioid dimers also showed a second, less prominent sym-
metric interface, involving TM1, TM2, and helix 8 (H8; the helix adjacent to TM7 
running along the internal membrane surface [75]). For GPCRs, the majority of 
crystal structures that are currently available refer to antagonist-bound (inactive) 
structures. The inferred dimeric interfaces may, therefore, depend on specific 
conformational states. Furthermore, the TM5-TM6 interface inferred by the 
crystal structure of μ-opioid dimers could preclude either monomer from properly 
coupling to G protein, because the agonist-induced receptor-G protein interaction 
depends on rearrangements of TM5 and TM6 within the seven-helical domain 
bundle, suggesting that different receptor conformations stabilized with different 
ligands may also promote different dimeric interfaces [75]. Huang et al. [76] sug-
gested that the comparison of the differences in the interfaces observed from the 
crystallized structures of the antagonist-bound μ-opioid and chemokine CXCR4 
receptors and the ligand-free β1-adrenoceptor suggest that the TM5 interface can 
partner in the interaction with TM4 or TM6, depending on the conformation of 
the receptor.
In δ-μ-OR heteromers, it was shown that binding and signaling by morphine 
or μ receptor agonists were potentiated by δ-OR antagonists, and reciprocally, 
binding and signaling by δ-OR agonists were potentiated by μ receptor selec-
tive antagonists [77, 78]. Studies carried out with the δ-opioid-cannabinoid CB1 
receptor heteromer have also revealed allosteric modulations of cannabinoid CB1 
receptor ligands on δ-OR ligand binding properties [79, 80]. They also showed 
that in recombinant systems expressing both receptors, as well as endogenous tis-
sues, binding and consequently signaling by δ-OR could be potentiated by a low, 
nonsignaling dose of cannabinoid CB1 receptor agonist or a selective antagonist. 
In the δ-μ-OR heteromers, Gupta et al. [81] showed that morphine-induction 
increases heteromer abundance. Similarly, the δ-opioid-CB1 receptor heteromer 
increases in the brain after peripherally elicited neuropathic pain [79]. Studies by 
Zheng et al. [82] have revealed a complex interplay among cholesterol, palmitate, 
receptor dimerization, and G protein activation. They showed that reducing cho-
lesterol levels or preventing palmitoylation of the μOR reduced receptor dimer-
ization and Gα association. Additionally, preventing palmitoylation reduced the 
association of μOR with cholesterol, suggesting a functional complex of receptor, 
palmitate, and cholesterol. The authors also demonstrate that mutagenesis of 
the palmitoylated cysteine residue in μOR has no effect on ligand binding but 
decreased signaling efficiency, probably by impairing GPCR-G protein associa-
tion. The same mutant had significantly reduced dimerization, and it was pro-
posed that this was responsible for the reduced G protein coupling. Zhang et al. 
[83] demonstrated that the palmitate-free mutant associated more weakly with 
cholesterol. A model of the μOR dimer in which cholesterol and palmitate pack 
together to facilitate receptor dimerization reveals that cholesterol interactions 
contribute approximately 25% of the total interaction energy at the homodimer 
interface [82].
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3.7 Receptor dimerization and immune cell stimulation and functioning
Chemokines are chemotactic cytokines that mediate their effects on leukocytes 
through a number of G protein-coupled, seven transmembrane-spanning (STM) 
receptors [84]. Specificity is provided by patterns of receptor and G protein expres-
sion, ligand potency, and levels of receptor desensitization. Interactions among 
receptors are mediated through a process known as receptor cross regulation, or 
heterologous desensitization [85]. Ali et al. [86] showed that thrombin receptor 
activation causes phosphorylation of several chemoattractant receptors, including 
the IL-8 receptor CXCR1, the C5a receptor, and the receptor for platelet-activating 
factor 3. Ben-Baruch et al. [87] have shown that homologous desensitization 
through phosphorylation of the IL-8 receptor CXCR2 occurs in response to its native 
ligands IL-8 and neutrophil-activating peptide (NAP)-2. Grimm et al. [28] showed 
that opiates, acting through δ and μ subclasses of opioid receptors expressed on 
human monocytes and neutrophils, are capable of inhibiting subsequent migra-
tory responses to chemokines, and that this process of heterologous desensitization 
or trans-deactivation is associated with phosphorylation of chemokine receptors. 
Szabo et al. [88] showed that the chemotactic activities of both μ- and δ-OR are 
desensitized following activation of the chemokine receptors CCR5, CCR2, CCR7, 
and CXCR4 but not of CXCR1 or CXCR2 receptors. The inhibition of CCL3 and 
CCL5 responses following opioid pretreatment is consistent with the desensitiza-
tion of either CCR1 or CCR5 or both. This receptor cross talk results in heterologous 
desensitization and phosphorylation of some of the chemokine receptors, which 
subsequently contribute to the immunosuppressive effects of the opioids.
4. Immune receptors and their function
Cells of the immune system intercommunicate by ligand-receptor interactions 
between cells and/or via secreted molecules called cytokines. Cytokines produced 
by lymphocytes are termed lymphokines (i.e., interleukins & interferon-γ), and 
those produced by monocytes and macrophages are termed monokines [89]. The 
T cells B cells NK cells Monocytes/
macrophages
Antigen recognition + + − −
Antigen presentation − + − +
Antibody production − + − −
Cellular immunity + − − +
Immune regulation + − + +
Phagocytosis − − − +
Cytotoxicity + − + +
Receptor TcR IgM & 
IgD
CD16 CD11b
Other surface markers CD3, CD4, 
CD8
CD19–21 CD56 CD14
Mononuclear cells in blood 
(%)
~75 ~10 10 5
Table 2. 
Major features and functions of mononuclear leukocytes.
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main receptors in the immune system are pattern recognition receptors (PRRs), 
Toll-like receptors (TLRs), killer activated and killer inhibitor receptors (KARs 
and KIRs), complement receptors, Fc receptors, and B & T cell receptors. Many are 
Figure 1. 
Principal surface markers of lymphocyte populations.
Figure 2. 
Diagram showing CD markers on various immune cell types.
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phagocytic receptors that stimulate ingestion of the pathogens they recognize. Some 
are chemotactic receptors, such as the f-Met-Leu-Phe receptor, which binds the 
N-formylated peptides produced by bacteria and guide neutrophils to sites of infec-
tion. A third function, which may be mediated by some of the phagocytic receptors 
as well as by specialized signaling receptors, is to induce effector molecules that 
contribute to induce innate immune responses and molecules that influence the 
initiation and nature of any subsequent adaptive immune response [1]. Various 
immune cell functions regulated by receptors on immunocytes are summarized in 
Table 3 and Figure 3.
5. CD14 receptor coactivation with μOR: effect on cell division and 
NF-κΒ phosphorylation
LPS-mediated lymphocyte activation and effect of costimulation with opioid 
receptor agonists were studied by treating the cells with the μOR agonist DAMGO for 
time intervals of 5, 30, or 240 min. A549, a cell line having both CD14 and μOR, was 
used to study the effect on cell proliferation and NFκΒ phosphorylation. Treatment 
of A549 revealed that DAMGO was able to mitigate the LPS-mediated induction of 
phosphorylated NFκB after cotreatment for 4 h (Figure 2). Similarly, DAMGO was 
also able to suppress the cell proliferation by LPS, significantly reducing the percent-
age of cells in M-phase as well as in S-phase of the cell cycle (Tables 2 and 3).
6. Effect of μOR activation with a selective ΚOR agonist and μOR 
antagonist
The effect of coactivation of two different opioid receptors, U50488, a selective 
KOR agonist was used for lymphocyte activation, and effect of costimulation of μOR 
was achieved by using DAMGO, an opioid receptor agonist. Cells were treated with 
μOR agonists DAMGO for varying time intervals, and effect on cell proliferation and 
NF-κΒ phosphorylation was studied. Results using HepG2 revealed that U50488 (an 
agonist for KOR) was able to mitigate the effect of DAMGO, an agonist for μOR, and 
a significant reduction in the percentage of cells in both M-phase and S-phase of the 
cell cycle was observed at 2 and 24 h of treatment. U50488 alone also showed a larger 
percentage of cells in G0 phase both at 2 and 24 h in comparison with DAMGO, and 
the mitigation of U50488 induced effects indicating cross talk of receptors (Figure 3).
Treatment Cell population in 
M phase (%)
Paired T-test Cell population in 
S-phase (%)
Paired T-test
LPS 6.071,2 15.74, 5
DAMGO 4.831,3 P < 0.00011 10.54, 6 p = 0.0294
LPS + DAMGO 3.892,3 P < 0.00012,
p = 0.00183
7.995, 6 p = 0.00015,
p = 0.0026
1NT vs. LPS.
2NT vs. DAMGO.
3NT vs. LPS + DAMGO.
4LPS vs. DAMGO.
5LPS vs. LPS + DAMGO.
6DAMGO vs. LPS + DAMGO.
Table 3. 
Effect of LPS and DAMGO on cell proliferation at 2 h after treatment.
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Our studies show that U50488, agonist for κOR, was able to mitigate the effect 
of DAMGO, an agonist for MOR and a significant reduction in the percentage 
of cells in both M-phase and S-phase of cell cycle was observed at 2 and 24 h of 
treatment (Table 4).
7. Effect of μOR coactivation on cell proliferation
Receptor-receptor interactions and di/oligomerization are established path-
ways for altering response to any given ligand. As both homo- and heterodimers 
of μOR have been reported, it is speculated that dimerization of μOR may have a 
role in regulating receptor signaling. This intermolecular cross talk within recep-
tor oligomers often results in allosterism between the different binding pockets of 
the individual monomers. Negative binding cooperativity has been observed for 
both GPCR homo- and heteromers using equilibrium binding and/or radio ligand 
dissociation [90].
Assays with TLR and μOR coactivation showed that agonist activation of μOR 
using DAMGO causes a significant lowering of LPS-induced cell division in cells 
coexpressing μOR and TLR. This has direct bearing on pathogen clearance as TLRs 
are present and expressed in sentinel cells such as macrophages and dendritic cells, 
which recognize structurally conserved molecules derived from microbes. These 
large phagocytes are found in essentially all tissues where they patrol for potential 
pathogens by amoeboid movement. These cells play a critical role in nonspecific 
Figure 3. 
Effect of cotreatment with agonist of OPRM1 (DAMGO) and agonist of CD-14 receptor (LPS) on NF-κΒ 
phosphorylation.
Treatment Cell population in 
M phase (%)
Paired T-test Cell population in S 
phase (%)
Paired T-test
DAMGO 26.661,2 9.404,5
U50488 14.151,3 P < 0.00011 14.154,6 p < 0.0014
U50488+ 
DAMGO
17.862,3 P < 0.00012,
p < 0.0001
8.075,6 p < 0.00015
p = 0.00026
1.4DAMGO vs U50488.
2.5DAMGO vs U50488 + DAMGO.
3.6U50488 vs U50488+ DAMGO.
Table 4. 
Effect of U50488 and DAMGO on cell proliferation at 2 h after treatment.
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defense (innate immunity) and also help initiate specific defense mechanisms 
(adaptive immunity) by recruiting other immune cells such as lymphocytes. 
Where a pathogen is involved, monocytes are commonly preceded by neutrophils, 
which release a range of toxic agents designed to kill extracellular pathogens. The 
macrophages then clear out both the dead pathogens and the dead neutrophils. The 
process of recruitment of neutrophils and macrophages involves the activation of 
resident macrophages. Activated resident macrophages respond to local stimuli by 
producing cytokines that make the endothelial cell surface more sticky (through 
induction of increased expression of cell adhesion molecules such as P-selectin) and 
chemokines, that promote and direct migration of inflammatory cells. Macrophages 
treated with LPS express high levels of cyclin D2 [91]. The CD14 and TLR signaling 
funnels into the activation of NF-κB, AP-1 and IRF3 pathways via the ERK1/2 and 
MEK1/2 channel, which is also activated by μOR signaling. Both signaling pathways 
funnel into the MAPK cascade and hence effect the activation of NFκΒ. Preliminary 
data from our study using both A549 and HepG2 cells show a significant decrease 
in LPS-induced cell division in the simultaneous presence of ligands for μOR. Cell 
cycle arrest was observed primarily in the S and the M phase of cell cycle with a sig-
nificant decrease under conditions of costimulation with both the receptor agonists. 
Cell cycle arrest observed as a result of receptor coactivation needs to be further 
explored as it can have important therapeutic implications as on one hand a particu-
lar signaling pathway or end point is associated with a therapeutic response, such as 
analgesic effect of opioids, while on the other hand it is associated with unwanted 
side effects, namely cell cycle suppression on exposure to LPS and opioids together.
Receptor heteromers, with their allosteric properties, give rise to a new kind of 
pharmacological target. The ability of one of the protomers to act as an allosteric 
modulator of the second protomer in the receptor heteromer gives the possibility of 
finding selective ligands for the protomer acting as conduit of the allosteric modula-
tion [73]. As opioid drugs are used in more than one clinical condition understand-
ing opioid receptor interactions with other GPCRs on the surface of different cell 
types can prove to be very beneficial in managing adverse, unwanted effects of these 
important therapeutic molecules. The immunomodulatory effects of morphine have 
been characterized both in animal and human studies and was found to decrease 
several functions of both natural and acquired immunity, interfering with important 
intracellular pathways involved in immune regulation [92]. Opiates namely mor-
phine, heroin, fentanyl and methadone all induce immune-suppression and affect 
both innate and adaptive immunity defining a role of μOR in these functions.
8. Association of OPRM1 functional alleles with immune cell function
Sharad et al. [93] used a genetic approach to correlate a functional OPRM1 gene 
polymorphism with known action of opiates on immunity and undertook a prospec-
tive study to understand the relationship of the 118G variation with the amount 
of exogenous opiates consumed and correlated the immunosuppressive effects of 
exogenous opiates with the OPRM1 allele type. They studied the immune status 
of opiate users by measuring serum Ig (IgG and IgA) levels, in association with 
specific OPRM1 genotype, and confirmed that the mean circulating levels of Ig were 
significantly lower in opiate users when compared with levels in cohort controls. 
Among opiate-dependent subjects, individuals with AA genotype were found to have 
the lowest levels of circulating immunoglobulins, both IgG and IgA (p = 0.0001), 
while the AG genotype carrying individuals had a higher level of both immuno-
globulins. The homozygous GG genotype was in between the AA and AG genotypes. 
Alternatively, in opiate naïve subjects, the AA individuals showed the highest titers of 
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circulating IgG, and the GG individuals showed the lowest with AG having inter-
mediate values [94]. The immunosuppressive effects documented in opiate naïve 
individuals can be attributed to altered regulation of PKA and pERK1/2 due to the 
levels of endogenous opioid. In addition to the absence of G genotype in the immor-
talized cell lines and based on the cell culture data showing cell cycle arrest observed 
in the present study (in A549 and HepG2 cell lines), we hypothesize that coactivation 
of μOR in presence of 118G allele leads to a suppression/arrest of cell division.
To test this hypothesis, another pilot study was carried out in which healthy 
opiate naïve volunteers were enrolled and the cell count for circulating lymphocyte 
subsets was studied as a measure of immune competence. Genotypic association 
studies showed a correlation between the immune cell numbers. Total lymphocyte 
count showed a significant lowering in cell numbers in 118G-allele-bearing indi-
viduals when compared to 118A-bearing individuals. However, cell numbers in all 
individuals remained within the documented normal range of 500–4000 cell/ml. 
The GG allele individuals showed significantly lower cell count, averaging 490, 
which differed markedly from cell numbers observed in AA-bearing individuals 
with mean numbers of 1976 cells/ml, (p = 0.008) and a correlation factor, r2 of 
0.79 between the genotype and average cell numbers. Our data show a significant 
lowering in all immunocytes, namely leucocyte populations (CD45+ve cells), B 
lymphocytes (CD10+ve cells), T lymphocytes (CD3, CD4, and CD8+ve cells), NK 
cells (CD56+ve cells), activated monocytes (CD 11b+ve cells), and mesenchymal 
progenitors in GG-bearing individuals when compared to AA-allele-bearing indi-
viduals but not always in comparison with those bearing the AG allele. This baseline 
lowering of cell numbers in GG-bearing individuals supports the hypothesis that 
GG genotype suppresses cell division, and since mounting of a successful immune 
response and/or overstimulation of immune system, as in case of patients with 
autoimmune disorders, depends on activation of both innate and adaptive immune 
responses, the 118G-bearing individuals would be prone to immune suppression 
due to lack of amplification by selective cell division, a critical step in elimination of 
the pathogen or an autoimmune response to an antigen.
9. Conclusion and future perspectives
In conclusion, there is a significant correlation between the circulating number 
of lymphocytes TH and Tc, B cells and NK cells, and the μOR allele present, and 
this difference can be further increased in the presence of exogenous opioids 
either during clinical treatment or substance dependence, as the 118G allele 
affects the process of cell division arresting cells at the S or M phase of the cell 
cycle, or by modulating the action of cell division–linked secretion of stimulat-
ing cytokines/chemokine known to induce clone-specific and cell type–specific 
proliferation, because of the propensity of opioid receptor to heterodimerize 
and to selectively bias the subsequent ligand engagement/s with the dimerized/
oligomerized receptors. This “subliminal immune suppression” in G allele–bear-
ing individuals can have far reaching impact on onset of diseases such as cancer 
and obesity (both have an element inflammation) and vaccination for infectious 
diseases and even dreaded diseases as cancer. This immune suppression will 
certainly lower the individual’s risk for autoimmune disorders such as rheumatoid 
arthritis, lupus, etc. The relationship between the μOR-mediated cell signaling 
and impact of stimulation of MOR as partner receptors, which influences binding 
of the second ligand in immunocytes and thereby the outcome on immune cells 
function in mounting and regulating the immune response/s, needs more detailed 
molecular exploration.
Immune Response Activation and Immunomodulation
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